Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Feb 1;205(3):360-364.
doi: 10.1164/rccm.202105-1212LE.

Phenotypes of Patients with COVID-19 Who Have a Positive Clinical Response to Helmet Noninvasive Ventilation

Domenico Luca Grieco  1   2 , Luca S Menga  1   2 , Melania Cesarano  1   2 , Savino Spadaro  3 , Maria Maddalena Bitondo  4 , Cecilia Berardi  1   2 , Tommaso Rosà  1   2 , Filippo Bongiovanni  1   2 , Salvatore Maurizio Maggiore  5   6 , Massimo Antonelli  1   2 ; COVID-ICU Gemelli Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Phenotypes of Patients with COVID-19 Who Have a Positive Clinical Response to Helmet Noninvasive Ventilation

Domenico Luca Grieco et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Kaplan-Meier plots of the cumulative incidence of intubation from randomization to Day 28 in the subgroup of patients with PaCO2 of less than 35 mm Hg (n = 59 patients) and 35 mm Hg or more (n = 50 patients) at study enrollment. The hazard ratio for endotracheal intubation in the helmet noninvasive ventilation group in patients with PaCO2 of less than 35 mm Hg was 0.25 (95% CI, 0.11–0.57). The hazard ratio for endotracheal intubation in the helmet noninvasive ventilation group in patients with PaCO2 of at least 35 mm Hg was 1.05 (95% CI, 0.44–2.53). (B) Kaplan-Meier plots of the cumulative incidence of intubation from randomization to Day 28 in the subgroup of patients with PaO2/(FiO2 × dyspnea) lower (n = 54 patients) and equal to or higher than (n = 55 patients) 30 at study enrollment. The hazard ratio for endotracheal intubation in the helmet noninvasive ventilation group in patients with PaO2/(FiO2 × VAS dyspnea) < 30 was 0.39 (95% CI, 0.19–0.82). The hazard ratio for endotracheal intubation in the helmet noninvasive ventilation group in patients with PaO2/(FiO2 × VAS dyspnea) ⩾ 30 was 0.63 (95% CI, 0.23–1.73). CI = confidence interval; VAS = visual analog scale.
See this image and copyright information in PMC

References

    1. Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al. COVID-ICU Gemelli Study Group Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA . 2021;325:1731–1743. - PMC - PubMed
    1. Munshi L, Hall JB. Respiratory support during the COVID-19 pandemic: is it time to consider using a helmet? JAMA . 2021;325:1723–1725. - PubMed
    1. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med . 2019;199:1368–1376. - PubMed
    1. Dres M, Similowski T, Goligher EC, Pham T, Sergenyuk L, Telias I, et al. Dyspnoea and respiratory muscle ultrasound to predict extubation failure. Eur Respir J . 2021;58:2100002. - PubMed
    1. Dangers L, Montlahuc C, Kouatchet A, Jaber S, Meziani F, Perbet S, et al. REVA Network (Research Network in Mechanical Ventilation) and the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie (GrrrOH) List of contributors who included study patients: Angers University Hospital, Angers, France. Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: a prospective observational study. Eur Respir J . 2018;52:1702637. - PubMed

Publication types

LinkOut - more resources